Conference call to discuss new data presented for duvakitug (Anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organization (ECCO) to be held on February 24 at 8 am. Webcast Link
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study
- Teva, Alvotech announces U.S. availability of SELARSDI injection
- Alvotech and Teva’s BLA filing for AVT06 accepted by FDA
- Biotech Alert: Searches spiking for these stocks today
- TD ups Axsome target, sees takeout speculation on patent settlement